Browse Guides  internal medicine  cardiology

Acute coronary syndrome

Prevalence
Clinical features
Differential diagnosis
Investigations
Therapy
Prevention
Prognosis
Therapy

With ECG changes or elevated cardiac enzymes

There is no clear benefit from using lamifiban a

Why?

  • Patients with acute coronary syndrome who received lamifiban compared with placebo were not less likely to have die, have a myocardial infarction or severe recurrent ischaemia. a

 

Expiry date: June 2003
Levels of Evidence used in grading these guides

Authors   CM   Ball , N   Shenker
Reviewer   I K   Jang
CAT Writers   N   Shenker , CJ   Wotton , CM   Ball , RS   Phillips